ZVRA Zevra Therapeutics Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: ZVRA

Price (delayed)

$11.22

Market cap

$663.27M

P/E Ratio

5.47

Dividend/share

N/A

EPS

$2.05

Enterprise value

$568.82M

?
Relative Growth: Rel. Growth: 97
Relative Strength: Rel. Strength: 73
Relative Valuation: Rel. Valuation: 95
Relative Profitability: Rel. Profitability: 95

KemPharm is a specialty pharmaceutical company focused on the discovery and development of proprietary prodrugs to treat serious medical conditions through its proprietary LAT™ (Ligand Activated Therapy) technology. KemPharm utilizes ...

Highlights
ZVRA's debt has dropped by 98% since the previous quarter and by 98% year-on-year
Zevra Therapeutics's net income has increased by 49% QoQ
The quick ratio has surged by 70% year-on-year but it has declined by 13% since the previous quarter
Sector: Healthcare
Industry: Biotechnology
Website: http://www.kempharm.com
Peers: OPK ORGO

Key stats

What are the main financial stats of ZVRA

ZVRA stock price

How has the Zevra Therapeutics stock price performed over time
Intraday
2.37%
1 week
-1.58%
1 month
11.64%
1 year
25.36%
YTD
25.22%
QTD
20.39%

Financial performance

How have Zevra Therapeutics's revenue and profit performed over time
Revenue
$122.29M
Gross profit
$105.26M
Operating income
-$5.44M
Net income
$124.22M
Gross margin
86.1%
Net margin
101.6%
ZVRA's net margin has surged by 145% year-on-year and by 30% since the previous quarter
The operating margin has soared by 98% YoY and by 93% from the previous quarter
The operating income has soared by 92% YoY and by 91% from the previous quarter
Zevra Therapeutics's net income has increased by 49% QoQ

Price vs fundamentals

How does ZVRA's price correlate with its fundamentals

Growth

What is Zevra Therapeutics's growth rate over time

Valuation

What is Zevra Therapeutics stock price valuation
P/E
5.47
P/B
3.2
P/S
5.36
EV/EBIT
4.03
EV/EBITDA
3.93
EV/Sales
4.65
Zevra Therapeutics's EPS has increased by 46% QoQ
Zevra Therapeutics's equity has increased by 33% from the previous quarter
The price to book (P/B) is 20% lower than the 5-year quarterly average of 3.9 and 11% lower than the last 4 quarters average of 3.5
ZVRA's P/S is 53% below its 5-year quarterly average of 11.2 and 10% below its last 4 quarters average of 5.8
ZVRA's revenue is up by 15% QoQ

Efficiency

How efficient is Zevra Therapeutics business performance
Zevra Therapeutics's return on invested capital has surged by 188% YoY and by 44% QoQ
The company's return on assets has surged by 185% YoY and by 35% QoQ
Zevra Therapeutics's return on sales has surged by 170% YoY and by 30% QoQ
ZVRA's ROE has soared by 140% YoY and by 9% QoQ

Dividends

What is ZVRA's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for ZVRA.

Financial health

How did Zevra Therapeutics financials performed over time
The quick ratio has surged by 70% year-on-year but it has declined by 13% since the previous quarter
The company's current ratio has surged by 62% YoY but it fell by 14% QoQ
ZVRA's debt is 99% smaller than its equity
The debt to equity has plunged by 99% YoY and by 98% from the previous quarter
ZVRA's debt has dropped by 98% since the previous quarter and by 98% year-on-year

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.